Connection

William Creasman to Neoplasm Staging

Back to Details
This is a "connection" page, showing publications William Creasman has written about Neoplasm Staging.
William Creasman
Connection Strength
1.947
Neoplasm Staging
  1. History of the FIGO cancer staging system. Int J Gynaecol Obstet. 2008 May; 101(2):205-10.
    View in: PubMed
    Score: 0.252
  2. Why do we continue to overtreat stage Ia?carcinoma of the cervix? Am J Obstet Gynecol. 2017 10; 217(4):413-417.
    View in: PubMed
    Score: 0.120
  3. Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. Gynecol Oncol. 2017 06; 145(3):519-525.
    View in: PubMed
    Score: 0.120
  4. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009 May; 105(2):109.
    View in: PubMed
    Score: 0.069
  5. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S105-43.
    View in: PubMed
    Score: 0.058
  6. Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A [corrected]. Gynecol Oncol. 2005 Sep; 98(3):467-83.
    View in: PubMed
    Score: 0.054
  7. Vaginal cancers. Curr Opin Obstet Gynecol. 2005 Feb; 17(1):71-6.
    View in: PubMed
    Score: 0.051
  8. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol. 2004 Dec; 95(3):593-6.
    View in: PubMed
    Score: 0.051
  9. Carcinoma of the vulva. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:7-26.
    View in: PubMed
    Score: 0.047
  10. Carcinoma of the vagina. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:27-39.
    View in: PubMed
    Score: 0.047
  11. Carcinoma of the corpus uteri. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:79-118.
    View in: PubMed
    Score: 0.047
  12. Gestational trophoblastic diseases. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:167-74.
    View in: PubMed
    Score: 0.047
  13. Stage IA cancer of the cervix: finally some resolution of definition and treatment? Gynecol Oncol. 1999 Aug; 74(2):163-4.
    View in: PubMed
    Score: 0.035
  14. Significance of true surgical pathologic staging: a Gynecologic Oncology Group Study. Am J Obstet Gynecol. 1999 Jul; 181(1):31-4.
    View in: PubMed
    Score: 0.035
  15. The National Cancer Data Base report on cancer of the vagina. Cancer. 1998 Sep 01; 83(5):1033-40.
    View in: PubMed
    Score: 0.033
  16. Receipt of adjuvant endometrial cancer treatment according to race: an?NRG Oncology/Gynecologic Oncology Group 210 Study. Am J Obstet Gynecol. 2018 11; 219(5):459.e1-459.e11.
    View in: PubMed
    Score: 0.033
  17. Early invasive carcinoma of the cervix (3 to 5 mm invasion): risk factors and prognosis. A Gynecologic Oncology Group study. Am J Obstet Gynecol. 1998 Jan; 178(1 Pt 1):62-5.
    View in: PubMed
    Score: 0.031
  18. Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. Int J Cancer. 2018 03 15; 142(6):1102-1115.
    View in: PubMed
    Score: 0.031
  19. The National Cancer Data Base report on early stage invasive vulvar carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1997 Aug 01; 80(3):505-13.
    View in: PubMed
    Score: 0.031
  20. Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 1997 Aug; 66(2):171-8.
    View in: PubMed
    Score: 0.031
  21. Synuclein-? in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer. 2017 04 01; 123(7):1144-1155.
    View in: PubMed
    Score: 0.029
  22. Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Dec; 143(3):511-515.
    View in: PubMed
    Score: 0.029
  23. New gynecologic cancer staging. Gynecol Oncol. 1995 Aug; 58(2):157-8.
    View in: PubMed
    Score: 0.027
  24. Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial. J Natl Cancer Inst. 2015 Sep; 107(9).
    View in: PubMed
    Score: 0.026
  25. Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study. Gynecol Oncol. 1995 Jun; 57(3):412-6.
    View in: PubMed
    Score: 0.026
  26. Adverse effect of electrosurgical loop excision on assignment of FIGO stage in cervical cancer: report of two cases. Gynecol Oncol. 1994 Nov; 55(2):313-7.
    View in: PubMed
    Score: 0.025
  27. Limited disease: role of surgery. Semin Oncol. 1994 Feb; 21(1):79-83.
    View in: PubMed
    Score: 0.024
  28. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013 May; 129(2):277-84.
    View in: PubMed
    Score: 0.022
  29. Prognostic significance of hormone receptors in endometrial cancer. Cancer. 1993 Feb 15; 71(4 Suppl):1467-70.
    View in: PubMed
    Score: 0.022
  30. Adenocarcinoma of the uterine corpus. Curr Opin Obstet Gynecol. 1993 Feb; 5(1):80-3.
    View in: PubMed
    Score: 0.022
  31. Revision in classification by International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol. 1992 Sep; 167(3):857-8.
    View in: PubMed
    Score: 0.022
  32. Epithelial ovarian tumors of low malignant potential. Obstet Gynecol. 1991 Dec; 78(6):1027-32.
    View in: PubMed
    Score: 0.021
  33. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer. 1991 Jul 15; 68(2):269-71.
    View in: PubMed
    Score: 0.020
  34. A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1990 Dec; 39(3):239-43.
    View in: PubMed
    Score: 0.019
  35. New gynecologic cancer staging. Obstet Gynecol. 1990 Feb; 75(2):287-8.
    View in: PubMed
    Score: 0.018
  36. Recent advances in endometrial cancer. Semin Surg Oncol. 1990; 6(6):339-42.
    View in: PubMed
    Score: 0.018
  37. Second-look laparotomy in the patient with minimal residual stage III ovarian cancer (a Gynecologic Oncology Group Study). Gynecol Oncol. 1989 Dec; 35(3):378-82.
    View in: PubMed
    Score: 0.018
  38. Prognostic factors in relation to second-look laparotomy in ovarian cancer. Baillieres Clin Obstet Gynaecol. 1989 Mar; 3(1):183-90.
    View in: PubMed
    Score: 0.017
  39. Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol. 2007 Aug; 106(2):362-9.
    View in: PubMed
    Score: 0.015
  40. Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging. Am J Obstet Gynecol. 1987 May; 156(5):1153-8.
    View in: PubMed
    Score: 0.015
  41. Papanicolaou smear history of patients developing cervical cancer: an assessment of screening protocols. Obstet Gynecol. 1987 Feb; 69(2):151-5.
    View in: PubMed
    Score: 0.015
  42. Management of endometrial adenocarcinoma stage I with surgical staging followed by tailored adjuvant radiation therapy. Clin Obstet Gynaecol. 1986 Dec; 13(4):751-65.
    View in: PubMed
    Score: 0.015
  43. Carcinoma of the fallopian tube. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S145-60.
    View in: PubMed
    Score: 0.015
  44. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S161-92.
    View in: PubMed
    Score: 0.015
  45. Gestational trophoblastic neoplasia. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S193-203.
    View in: PubMed
    Score: 0.015
  46. Carcinoma of the vagina. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S29-42.
    View in: PubMed
    Score: 0.015
  47. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S43-103.
    View in: PubMed
    Score: 0.015
  48. Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S7-27.
    View in: PubMed
    Score: 0.015
  49. The significance of peritoneal cytology in patients with carcinoma of the cervix. Gynecol Oncol. 1984 Feb; 17(2):139-48.
    View in: PubMed
    Score: 0.012
  50. Cryosurgery in the management of cervical intraepithelial neoplasia. Obstet Gynecol. 1984 Feb; 63(2):145-9.
    View in: PubMed
    Score: 0.012
  51. Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:41-78.
    View in: PubMed
    Score: 0.012
  52. Carcinoma of the Fallopian tube. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:119-33.
    View in: PubMed
    Score: 0.012
  53. Carcinoma of the ovary. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:135-66.
    View in: PubMed
    Score: 0.012
  54. The role of adjuvant therapy in Stage I ovarian cancer. Am J Obstet Gynecol. 1980 Sep 15; 138(2):139-45.
    View in: PubMed
    Score: 0.009
  55. Results and complications of operative staging in cervical cancer: experience of the Gynecologic Oncology Group. Gynecol Oncol. 1980 Feb; 9(1):90-8.
    View in: PubMed
    Score: 0.009
  56. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet. 1999 Jun; 65(3):243-9.
    View in: PubMed
    Score: 0.009
  57. Unusual metastasis in carcinoma of the cervix uteri. Surg Gynecol Obstet. 1979 May; 148(5):728-30.
    View in: PubMed
    Score: 0.009
  58. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet. 1999 Jan; 64(1):5-10.
    View in: PubMed
    Score: 0.008
  59. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1995 Jul; 13(7):1589-99.
    View in: PubMed
    Score: 0.007
  60. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993 Feb 15; 71(4 Suppl):1702-9.
    View in: PubMed
    Score: 0.006
  61. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer. 1991 Oct 15; 68(8):1758-63.
    View in: PubMed
    Score: 0.005
  62. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991 Jan; 40(1):55-65.
    View in: PubMed
    Score: 0.005
  63. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. Gynecol Oncol. 1990 Feb; 36(2):166-71.
    View in: PubMed
    Score: 0.005
  64. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol. 1990 Feb; 75(2):249-54.
    View in: PubMed
    Score: 0.005
  65. A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989 Dec; 35(3):314-20.
    View in: PubMed
    Score: 0.004
  66. Conservative surgical management of superficially invasive stage I vulvar carcinoma. Gynecol Oncol. 1989 Dec; 35(3):352-7.
    View in: PubMed
    Score: 0.004
  67. Endometrial adenocarcinoma estrogen receptor content: association of clinicopathologic features with immunohistochemical analysis compared with standard biochemical methods. Am J Obstet Gynecol. 1987 Oct; 157(4 Pt 1):924-31.
    View in: PubMed
    Score: 0.004
  68. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer. 1986 May 01; 57(9):1725-30.
    View in: PubMed
    Score: 0.004
  69. Intraperitoneal chromic phosphate P 32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma. Am J Obstet Gynecol. 1985 Sep 15; 153(2):191-6.
    View in: PubMed
    Score: 0.003
  70. Risk factors and recurrent patterns in Stage I endometrial cancer. Am J Obstet Gynecol. 1985 Apr 15; 151(8):1009-15.
    View in: PubMed
    Score: 0.003
  71. Cytoplasmic estrogen and progesterone receptor content of uterine sarcomas. Am J Obstet Gynecol. 1984 Oct 15; 150(4):342-8.
    View in: PubMed
    Score: 0.003
  72. Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes (a Gynecologic Oncology Group study). Gynecol Oncol. 1984 Sep; 19(1):8-16.
    View in: PubMed
    Score: 0.003
  73. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol. 1984 Jun; 63(6):825-32.
    View in: PubMed
    Score: 0.003
  74. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983 Aug 15; 52(4):626-32.
    View in: PubMed
    Score: 0.003
  75. Prognostic value of cytologic examination of peritoneal washings in patients with endometrial carcinoma. Acta Cytol. 1981 Nov-Dec; 25(6):640-6.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.